Categories
Change Password!
Reset Password!
Erenumab, an anti-CGRP receptor monoclonal antibody is a proven, effective, and safe option for migraine management in real-world clinical settings.
A novel systematic review provided robust evidence supporting the effectiveness and safety of Erenumab in real-world settings. This marks the first meta-analysis focusing on the real-world application of Erenumab, highlighting its potential as a reliable therapeutic option for migraine
Jaime Fernández-Bravo-Rodrigo et al. aimed to evaluate the efficacy and safety of Erenumab in decreasing the intensity and incidence of migraines in real-world scenarios. To look for relevant studies on the impact of Erenumab, a database search of Scopus, Web of Science, PubMed and Cochrane up to December 2023 was performed.
The meta-analysis included 53 studies, revealing significant reductions across multiple parameters at the 3-month mark:
Also, the benefits of Erenumab grew slightly over 6- and 12-month periods. Response rates revealed that about one-third of patients experienced a greater than 30% reduction in MMD/MHD, one-sixth had over 50%, and 3-4% of patients achieved a 100% response rate. The rates of adverse events were logged as 0.34 at 6 months and 0.43 at 12 months.
European Journal of Pharmacology
Real-world effectiveness and safety of Erenumab for the treatment of migraine: A systematic review and meta-analysis
Jaime Fernández-Bravo-Rodrigo et al.
Comments (0)